Albany, NY -- (SBWIRE) -- 08/26/2019 -- Dry Age-Related Macular Degeneration Market Insights, Epidemiology and Market Forecast-2028
1. Age-related Macular Degeneration affects approximately 1.8 million Americans aged 40 years and older.
2. Approximately 85–90% of the cases of macular degeneration are the "dry" type.
3. Age-Related Macular Degeneration global prevalence of any type of the disease was approximately 8.7%, with the prevalence of early Age-Related Macular Degeneration being 8.0% and the prevalence of late Age-Related Macular Degeneration being 0.4%.
DelveInsight launched a new report on Dry Age-Related Macular Degeneration Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Dry Age-Related Macular Degeneration market report covers a descriptive overview and comprehensive insight of the Dry Age-Related Macular Degeneration epidemiology and Dry Age-Related Macular Degeneration market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Dry Age-Related Macular Degeneration market report provides insights on the current and emerging therapies.
3. Dry Age-Related Macular Degeneration market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Dry Age-Related Macular Degeneration market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dry Age-Related Macular Degeneration market.
Request for sample pages
"Dry Age-Related Macular Degeneration develops in approximately 85% of all patients with Age-related Macular Degeneration."
Dry Age-Related Macular Degeneration treatment landscape only consists of dietary vitamin and other supplements. Currently, there is no approved therapy for Dry Age-Related Macular Degeneration treatment, and Dry Age-Related Macular Degeneration treatment is mainly focused on providing nutritional supplements to manage the disease.
People with lots of drusen or severe vision loss might benefit from taking a specific combination of nutritional supplements. Several different approaches are under development for treating nonexudative manifestations of age-related macular degeneration. Some interventions target specific pathways that are believed to play a role in Age-Related Macular Degeneration pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. ?-amyloid accumulation), impaired choroidal blood flow, and apoptosis.
For selected people with advanced dry macular degeneration in both eyes, one option is to improve the vision by surgery or by implanting a telescopic lens in one eye. The telescopic lens, which looks like a tiny plastic tube, is equipped with lenses that magnify the field of vision. The telescopic lens implant may improve both distance and close-up vision, but it has a very narrow field of view.
The global Dry Age-Related Macular Degeneration market has increased over the past few years. The Dry Age-Related Macular Degeneration market size is expected to increase by the major drivers such as rising prevalent population, technological advancements and upcoming therapies, strategies such as mergers and acquisitions, etc. However, many factors also hamper Dry Age-Related Macular Degeneration market growth of off-label therapies, high therapy cost, etc. Due to the absence of any approved therapies, Dry Age-Related Macular Degeneration market size is believed to experience modest growth during the forecast period due to the expected launch of novel therapies [2019-2028].
The launch of the emerging therapies is expected to significantly impact Dry Age-Related Macular Degeneration treatment scenario in the upcoming years:-
Drugs covered
1. Zimura
2. Risuteganib (ALG 1001)
3. LBS-008
And many others
The key players in Dry Age-Related Macular Degeneration market are:
1. Ophthotech Corporation
2. Allegro Ophthalmics
3. Lin Bioscience
4. Catalyst Bioscience
And many others
Table of contents
1. Report Introduction
2. Dry Age-Related Macular Degeneration Market Overview at a Glance
3. Dry Age-Related Macular Degeneration Disease Background and Overview
4. Dry Age-Related Macular Degeneration Epidemiology and Patient Population
5. Dry Age-Related Macular Degeneration Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.2.Germany
5.2.3.France
5.2.4.Italy
5.2.5.Spain
5.2.6.United Kingdom
5.3. Japan
6. Dry Age-Related Macular Degeneration Treatments & Medical Practices
7. Dry Age-Related Macular Degeneration Emerging Therapies
7.1. Key Cross Competition
7.2. Zimura: Ophthotech Corporation
7.3. Risuteganib: Allegro Ophthalmics
8. Dry Age-Related Macular Degeneration Market Size
9. 7MM Dry Age-Related Macular Degeneration Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. Italy Market Size
9.5. Spain Market Size
9.6. United Kingdom Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barriers
12. Appendix
13. Dry Age-Related Macular Degeneration Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight